This site is intended for health professionals only

Home / News / Dispensing / Billions to be lost by drug companies by end of decade

Billions to be lost by drug companies by end of decade

12 Dec 2014

Pharmaceutical companies will lose more than £40bn by 2019, due to patents on drugs expiring.

It is claimed companies such as Otsuka, Eli Lilly and AstraZeneca (AZ) will be affected the most, especially in the central nervous system (CNS) medication sector.

GlobalData analyst for healthcare industry dynamics, Adam Dion, said: “AZ’s CNS segment has been bleeding sales as a result of the company losing its patent on Seroquel, a treatment for bipolar disorder, allowing for cheaper generic alternatives.”

It is claimed AZ’s shares fell to 3% in 2013 from 9% in 2010.

Dion said Eli Lilly’s market share declined from 14.3% in 2010 to 11.2% in 2013, due to decreasing sales of the company’s medication for schizophrenia and bipolar disorder.

It is claimed Ablify, an anti-psychotic drug, produced by Otsuka, will have its US patent expire in 2015, meaning the drug is predicted to lose nearly £5bn by 2019 as a result of generic medications.

Want news like this straight to your inbox?

Latest News

Post-Brexit deal on medicines into Northern Ireland ‘urgently’ needed to avoid shortages, NPA warns
Brexit negotiators must reach an agreement on the supply of medicines from the UK into...
Lloyds Pharmacy
LloydsPharmacy owner looks to exit UK
The parent of LloydsPharmacy, McKesson, has sold a number of its European businesses, with the...
Nigel Clarke April 2014
GPhC chair Nigel Clarke to step down
The chair of the General Pharmaceutical Council (GPhC), Nigel Clarke, is to step down after...